Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria – an Ultra-Rare Genetic Disorder that Causes Rapid Aging
MIAMI, FLORIDA / ACCESS Newswire Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company focused on reversing biological aging and age-related diseases, today announced compelling new preclinical data showing that its lead candidate, Telomir-1, prevented cellular aging in human progeria cell lines obtained from the Progeria Research Foundation. Progeria, or Hutchinson-Gilford Progeria Syndrome (HGPS), is an ultra-rare pediatric disorder caused by a mutation in the LMNA gene. This mutation results in the production of an abnormal protein called progerin, which drives rapid biological aging in children.
There are an estimated 400-500 known cases worldwide, including fewer than 30 children currently living with the disease in the United States. Symptoms typically begin within the first two years of life and include growth failure, joint stiffness, loss of body fat and hair, and severe cardiovascular disease. Children with progeria have an average life expectancy of just 13 to 15 years, with most dying from heart attacks or strokes at a young age.
The only FDA-approved therapy for progeria, Zokinvy® (lonafarnib), is a farnesyltransferase inhibitor that has been shown to extend lifespan by an average of 4.3 years. However, Zokinvy does not reverse the underlying disease pathology or halt cardiovascular deterioration, which remains the leading cause of death. No approved therapy restores normal cell function or reverses the biological hallmarks of accelerated aging in progeria, highlighting a significant and urgent unmet medical need.
Telomir-1 is designed to regulate intracellular metal ions, reduce oxidative stress, restore mitochondrial function, extend telomere length, reverse muscle loss, and reset age-associated DNA methylation patterns – all of which are critical biological pathways implicated in progeria and broader age-related diseases.
In this study, conducted by Smart Assays, Telomir-1 was tested in cells taken directly from a child with HGPS. These cells were obtained from The Progeria Research Foundation (www.progeriaresearch.org). The study evaluated cell viability, reactive oxygen species (ROS), and intracellular calcium signaling – a marker of mitochondrial dysfunction – under both normal and stress-induced conditions.
Key findings include:
Improved cell viability: Telomir-1 increased survival in a dose-dependent manner, both under basal conditions and even under stress conditions induced by copper and iron-two metal ions known to accelerate aging by generating oxidative damage and destabilizing DNA and telomeres.
Reduction of oxidative stress: Progeria cells exhibited abnormally high levels of reactive oxygen species (ROS), a hallmark of cellular aging. Telomir-1 normalized these levels, both under basal conditions and even when ROS was further elevated by toxic metal exposure.
Restoration of mitochondrial function: Iron-induced calcium overload – a signal of mitochondrial damage and a known feature of HGPS – was significantly reduced with Telomir-1, indicating restored mitochondrial regulation and improved cellular energy balance.
These results demonstrate that Telomir-1 directly addresses the core cellular dysfunctions driving disease features in progeria – not only protecting cells from damage but restoring critical biological functions. The fact that these results were observed in actual patient-derived human cells offers strong early validation of Telomir-1's therapeutic potential.
'These results provide the strongest evidence to date that Telomir-1 is not only protective but also restorative at the molecular and cellular level,' said Dr. Angel, Chief Scientific Advisor of Telomir. 'What's especially promising is that the improvements we observed directly target the mechanisms known to drive disease progression in progeria – oxidative stress, metal toxicity, and mitochondrial instability. This level of functional rescue in actual patient-derived cells is highly encouraging as we move toward clinical translation. These studies come as further validation of the very promising results obtained previously in both nematode and zebrafish models of adult progeria.'
'These findings deepen our conviction that Telomir-1 can be a first-in-class therapeutic platform for rare aging syndromes and broader age-related diseases,' said Erez Aminov, CEO of Telomir. 'By demonstrating the ability to reverse cellular damage in human progeria cells, Telomir-1 represents a potential breakthrough for children who currently have no real options beyond modestly delaying the inevitable. This work also lays the foundation for broader applications in neurodegeneration, metabolic dysfunction, and systemic aging.
The new data also build on previously reported studies in zebrafish and C. elegans nematodes harboring the wrn gene mutation (a model of adult progeria, or Werner syndrome), where Telomir-1 significantly extended lifespan, restored telomere length, reversed muscle degeneration, and normalized molecular age markers.
Telomir is currently finalizing IND-enabling studies for Telomir-1 and plans to engage with the U.S. Food and Drug Administration (FDA) to explore regulatory pathways, including the potential for orphan drug designation. The company is evaluating multiple rare disease indications for initial clinical development.
Cautionary Note Regarding Forward-Looking Statements
This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.
Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at www.sec.gov. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact Information
SOURCE: Telomir Pharmaceuticals, Inc
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
Alembic Pharma acquires UK-based Utility Therapeutics for $12 million to expand US presence
Alembic Pharmaceuticals Inc., the wholly owned US subsidiary of Alembic Pharmaceuticals Limited, has announced the acquisition of UK-based Utility Therapeutics Ltd. This strategic move marks Alembic's entry into the branded anti-infective segment in the United States, particularly focusing on treatments for urinary tract infections (UTIs). Utility Therapeutics is engaged in developing pharmaceutical products aimed at combating UTIs, a widespread medical condition in the US. The acquisition brings two key assets into Alembic's fold — 'Pivya,' an FDA-approved treatment for uncomplicated UTIs, and 'MEC,' a pipeline product currently under development to address complicated UTI cases. Alembic Pharmaceuticals sees this acquisition as a significant step towards strengthening its presence in the US market with branded specialty products. The deal allows Alembic to market Utility's assets in the US, leveraging the regulatory approvals already in place and continuing the development of promising pipeline therapies. The total consideration for the acquisition is expected to be around $12 million, paid in a staggered manner depending on the achievement of specific milestones. It also includes a provision for profit sharing based on future earnings generated by Utility's products. The transaction does not fall under the related party category, and none of the promoters or group companies have any financial interest in the deal. Completion of the acquisition is anticipated within approximately 30 days, and no additional regulatory approvals are required. This acquisition aligns with Alembic's strategy of expanding its global footprint and diversifying its product offerings in regulated markets like the US. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Associated Press
4 hours ago
- Associated Press
Global Kratom Coalition Applauds FDA Action Against Hydroxie and Expects Broader Crackdown Against Synthetic Opioids Like 7
FDA action aligns with a growing chorus of scientists, public health experts, and advocates warning against the public health risk associated with the proliferation of 7 The Global Kratom Coalition (GKC) today commended the U.S. Food and Drug Administration (FDA) for issuing a comprehensive and forceful warning letter to Hydroxie, LLC, a seller of synthetic 7-hydroxymitragynine (otherwise known as '7') products falsely marketed as dietary supplements, shots, and drink mixes. The GKC hailed the move as a critical step in addressing these products that masquerade as natural dietary supplements but are actually unapproved new drugs. 'This warning letter is a major step in a broader effort to remove dangerous '7' products from store shelves and online marketplaces,' said Walker Gallman, Legislative Director of the Global Kratom Coalition. 'These actions should protect consumers and safeguard the integrity of the dietary supplement marketplace. It should result in a cascade of warnings to other 7 makers.' In the June 25, 2025, letter , the FDA identified multiple violations of the Food, Drug, and Cosmetic Act, citing Hydroxie's products as both unapproved new drugs and adulterated food. The FDA noted that Hydroxie's 7 products—including its 'Hydroxie 15mg 7-OH Tablets,' 'Hydroxie Red Shots,' and 'Hydroxie 7-OH Drink Mix"—are marketed with drug claims and contain an ingredient not generally recognized as safe. 'Your Hydroxie 15mg 7-OH Tablets, Hydroxie Red 15mg Tablets... are drugs as defined by section 201(g)(1) of the FD&C Act... because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease,' the FDA stated in the letter. 'Based on our review... the use of 7-OH in conventional food does not satisfy the criteria for GRAS status... [and] raises serious concerns about potential harm associated with 7-OH,' the agency warned. 'This is a watershed moment,' said Gallman. 'The FDA has now publicly and definitively recognized that products like Hydroxie's, which are made up of synthetically boosted and highly concentrated levels of 7-hydroxymitragynine, are deceptively marketed as dietary supplements or conventional foods and are illegal. They are not kratom products; they are not dietary supplements; they are not legal; they are unapproved drugs and adulterated foods masquerading as legal, natural products.' FDA Warning Letter Addresses Persistent 'Bad Actors' Damaging Industry The GKC has long warned that certain actors in the marketplace are undermining public trust in the dietary supplement industry by selling synthetically enhanced or adulterated 7 products, often under the guise of 'all natural' or 'dietary supplement' or as 'kratom'. However, these products are marketed by the companies that sell them and the advocacy organizations that support them ( Holistic Alternate Recovery Trust (HART) and 7-Hope Alliance ) as drugs to treat chronic pain and opioid use disorder. The FDA's letter made clear that: 7 has not been evaluated by the FDA for safe use. Without formal safety evaluation, consumers are left exposed to unknown risks from products that have never undergone rigorous scientific review. The FDA has received adverse event reports associated with 7. Reports of harm linked to 7 include serious side effects such as liver toxicity, seizures, and respiratory issues, underscoring the need for immediate regulatory scrutiny. 7 has opioid-like effects and poses unique safety concerns. Because concentrated, synthetic 7 is a novel, potent opioid receptor agonist, its presence in unregulated consumer products raises red flags about addiction, misuse, and overdose. 'We urge the FDA and state regulators to continue down this path,' said Gallman. 'The longer these products are on the market, the greater the threat to public safety.' A Growing Chorus of Concern About Synthetic 7-Hydroxymitragynine Products The FDA warning letter also adds to a growing chorus of scientists, researchers, and industry stakeholders who have issued concerns about 7 products. In reaction to the FDA warning letter on social media, Dr. Christopher R. McCurdy, PhD, from the University of Florida College of Pharmacy said , 'The FDA is taking action on semi-synthetic kratom alkaloid derivatives, and this is exactly what we count on the FDA to do! These non-kratom products need to be removed from the market as they are no different from the many synthetic cannabinoids that made up 'spice' and caused harm to many … These novel chemicals synthesized from kratom extracts are potent opioids and a public health threat as currently marketed. They might be beneficial if pursued through the same pathways that all novel drugs gain approval.' In a statement released last week, Dr. C. Michael White, Pharm.D., FCP, FCCP, FASHP, a pharmacist, distinguished professor of pharmacy practice at the University of Connecticut School of Pharmacy, and Kratom Consumer Advisory Council chair said: 'Selling potent opioid receptor-stimulating 7 products in gas stations, convenience stores, and smoke shops in unlimited quantities within arm's reach of candy bars and energy drinks is a public health recipe for disaster. It allows a whole new generation of consumers to potentially get hooked on opioids, and we know where that leads.' In late 2024, leading kratom researchers at Johns Hopkins University and the University of Florida issued urgent warnings about proliferation of 7 products and for its potential for abuse, dependence, severe withdrawal , and even respiratory depression, dangers that run directly counter to it being marketed as a treatment for opioid addiction. GKC Committed to Transparency and Science The Global Kratom Coalition will continue to encourage and support federal and state regulators to investigate vendors who make false or misleading claims about their products, particularly those promoting unapproved drugs disguised as dietary supplements. About Global Kratom Coalition The Global Kratom Coalition is an alliance of kratom consumers, experts, and industry leaders dedicated to protecting access to kratom while advancing scientific research, driving consumer education, and developing robust regulations to protect consumers. For more information, visit Media Contact Patrick George +1 916-202-1982 [email protected] ### SOURCE: Global Kratom Coalition Copyright 2025 EZ Newswire
WebMD
5 hours ago
- WebMD
Psoriasis: Why Biosimilar Drugs Are So Hard to Get
July 2, 2025 – For the more than 8 million Americans with psoriasis, biosimilars promised to drive down costs and improve access to treatment. But these medications, which are nearly identical to costlier biologics like Enbrel, Humira, Remicade, and Stelara, have faced various obstacles preventing more than a third of them from reaching market. The FDA says biosimilars have "no clinically meaningful differences" from the pricier name brands, at savings of 15% to 30% – or even more. Also known as "follow-on" drugs, biosimilars typically come out after the primary patent expires on the original biologic. Like biologics, they are made from living cells. Yet while 21 biosimilars have been approved for psoriasis, only 13 are currently available. Among the barriers: Insurers tend to favor name brands. Health insurers often give biologics preferential treatment on their list of drugs covered, called a formulary. That could be because pharmacy benefit managers negotiate larger rebates with biologic makers, and share that rebate with insurers, said Kavita Y. Sarin, MD, PhD, a professor of dermatology at Stanford Medicine. You may have to try the biologic first. Insurance plans often require patients to follow "step" therapy. That means trying other treatments (even if you've tried them before) and failing with them before getting approval to use a biosimilar. Legal battles drag on. Patent disputes over who owns the rights to the drug can delay access to a biosimilar, sometimes by several years. Most people don't know much about biosimilars. More than 70% of psoriasis patients have a poor understanding of biosimilars, according to an American Academy of Dermatology survey. The Need for Treatment The severity of psoriasis, a skin condition, varies greatly, according to the National Psoriasis Foundation. The key cause is an overactive immune system, leading to a rapid increase in skin cell production that forms raised, scaly patches on the skin, ranging in color from red to purple. Those affected report that it itches, burns, and stings. It's linked with other serious health conditions such as heart disease, diabetes, and depression. Treatment options include light therapy, topicals, nonsteroidal anti-inflammatory drugs, biologics, and biosimilars, among others. Yet support groups and social media communities are full of people looking for more help. The Long Trail of Approval The 21 biosimilars approved for psoriasis correspond to reference biologic products Enbrel, Humira, Remicade, and Stelara. The medications adjust the immune system and inhibit the processes that lead to inflammation and increased skin cell production. But the lag from approval to availability can be long. Adalimumab-atta (Amjevita) was approved in 2016 but did not become available until January 2023. Of the 16 adalimumab biosimilars FDA-approved for skin-related problems, the median time from approval to commercial access was just over a year, Sarin found. Many biosimilar makers are the same companies – or subsidiaries of the companies – that produce the original biologics, Sarin said, potentially giving them an incentive to delay or control competition. While there's no confirmed evidence of that happening, some biosimilar launches have been delayed after confidential settlements with originator companies. The Preserve Access to Affordable Generics and Biosimilars Act (S. 142), introduced in the U.S. Senate in March 2023, would prohibit such agreements – but the bill has stalled. Costs of biologics vary. As one example: Two pens of Humira can be $7,300, or $3,650 each, without insurance. A Humira biosimilar pen is listed online at $674. Biosimilars' Excellent Track Record "Our research shows that biosimilars are generally safe and effective for treating psoriasis, and doctors can feel confident prescribing them," said Duc Binh Phan, MSc, a research associate at the University of Manchester, U.K., who has evaluated research tracking how well biosimilars and biologics work. In one paper, he reviewed 16 studies of adalimumab, etanercept, and infliximab, with most evidence suggesting they were like the biologics in effectiveness and safety. One study did find a higher risk of adverse events with an adalimumab biosimilar. That points to the need for more studies to evaluate the real-world effectiveness, he said. But overall, "they work as well and as safely as the original (or 'originator') biologic drugs and can help more patients access treatment due to their lower cost," Phan said. He also found that those who switched from a biologic to a biosimilar were more likely to stop treatment, citing mild side effects, reactions where the shot went in, or going back to the original. That could be due to differences in the injection device or to psychological factors, Phan said. "Some patients might be wary of switching to a drug they perceive as 'cheaper' or not the same, which can affect how well they feel it works." He also cited the "nocebo effect" – when someone expects a treatment not to work and that leads to a worse experience. He advises doctors to tailor the treatment to the patient. It's also worth noting, Phan said, that some may develop an immune response to a biologic drug over time, making the treatment (and its biosimilars) less effective. In that case, switching to a different biologic with a different mode of action might be needed, he said. He urges ongoing research, as biologics are relatively new. The Old Switcheroo Even if you do get a prescribed biosimilar, it could be switched to a different product – another biosimilar or the original biologic – without warning, said Melissa C. Leeolou, a fourth-year medical student at Stanford University who co-authored a report with Sarin. "Medication substitution can occur when insurers or pharmacy benefit managers change formulary coverage, typically for financial reasons," Leeolou said. "If a biosimilar is designated as interchangeable to a reference biologic by the FDA, pharmacies in some states may substitute it for the reference product without notifying the prescriber [your doctor]." Even without that designation, the insurer may require a switch by denying coverage for the prescribed product. If the prescription switches to a less expensive product, any cost savings may go to the insurer or the pharmacy benefit manager, not the patient, Leeolou said. It depends on the plan, Sarin said. A Patient-Researcher's View "We're so lucky to have biologics," said Leeolou, a lifelong psoriasis patient. "It's important to know they exist as an alternative and [for patients] to talk to their doctors about them." Sarin suggests that patients with psoriasis become more aware – not just of access to and the promise of biosimilars, but of the possibility of being switched, once on a biosimilar, from one to another without being alerted. If that happens to you, you should tell your doctor, who may be able to help you figure out why the switch was made and answer any questions you may have about the new treatment. If coverage was denied, your doctor can request a prior authorization or file an appeal. A prescription marked "dispense as written" may help, but it doesn't always override insurer policies.
